{
    "clinical_study": {
        "@rank": "61968", 
        "arm_group": [
            {
                "arm_group_label": "bisoprolol", 
                "arm_group_type": "Experimental", 
                "description": "initially received 5 mg of bisoprolol (Concor\u00ae, Merck Serono, Darmstadt, Germany) once daily. The heart rate was assessed every two weeks. If the RHR was \u226465 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 10 mg Qd for bisoprolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8."
            }, 
            {
                "arm_group_label": "atenolol", 
                "arm_group_type": "Active Comparator", 
                "description": "initially received 50 mg atenolol (Beijing Double-Crane Pharmaceutical Co., Ltd, Beijing, China) once daily. The heart rate was assessed every two weeks. If the RHR was \u226465 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was  100 mg Qd for atenolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8."
            }
        ], 
        "brief_summary": {
            "textblock": "\u03b2-blockers (BBs) with different pharmacological properties may have heterogeneous effects on\n      sympathetic nervous activity (SNA) and central aortic pressure (CAP), which are independent\n      cardiovascular factors for hypertension. Hence, we analyzed the effects of bisoprolol and\n      atenolol on SNA and CAP in hypertensive patients."
        }, 
        "brief_title": "Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension", 
        "completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "condition": "Untreated Essential Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  25~65 years old\n\n          -  untreated essential hypertension\n\n          -  SBP 140-160mmHg & DBP 90-100mmHg\n\n          -  Sinus rhythm\n\n          -  Resting heart rate \uff1e70bpm\n\n          -  Can give written informed consent\n\n        Exclusion Criteria:\n\n          -  Atrial Fibrillation (AF)/ Sick Sinus Syndrome (SSS)/ atrioventricular    block 2-3\n             grade(AVB\u2161-\u2162) without pacemaker\n\n          -  Bradyarrhythmia/ hypotensive\n\n          -  Unstable Angina Pectoris (UAP)/AMI/ HF (NYHA class III - IV)\n\n          -  Uncontrolled diabetes mellitus (DM)\n\n          -  Bronchial asthma\n\n          -  Gastro-intestinal ulcer or skin ulcer\n\n          -  Liver dysfunction/ renal impairment\n\n          -  Treated with CCB (Calcium antagonists) ( except amlodipine) or other beta blocker.\n\n          -  Glaucoma\n\n          -  Known allergic/ intolerance to beta blocker\n\n          -  Pregnant or lactating women\n\n          -  Participation in another clinical study within the last 3 months\n\n          -  Legal incapacity or limited legal capacity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "109", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01762436", 
            "org_study_id": "Betablocker on CAP and BRS"
        }, 
        "intervention": [
            {
                "arm_group_label": "bisoprolol", 
                "intervention_name": "bisoprolol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "atenolol", 
                "intervention_name": "atenolol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atenolol", 
                "Bisoprolol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension and Department of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Study: Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "After 2-week maintenance treatment when the RHR was \u226465 bpm or at 8-week final visit", 
                "measure": "baroreflex sensitivity", 
                "safety_issue": "No", 
                "time_frame": "4~8 weeks"
            }, 
            {
                "description": "After 2-week maintenance treatment when the RHR was \u226465 bpm or at 8-week final visit", 
                "measure": "central aortic pressure", 
                "safety_issue": "No", 
                "time_frame": "4~8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01762436"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ruijin Hospital", 
            "investigator_full_name": "Weijun Zhou", 
            "investigator_title": "Associate Profeesor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "After 2-week maintenance treatment when the RHR was \u226465 bpm or at 8-week final visit", 
                "measure": "heart rate variability", 
                "safety_issue": "No", 
                "time_frame": "4~8 weeks"
            }, 
            {
                "description": "After 2-week maintenance treatment when the RHR was \u226465 bpm or at 8-week final visit", 
                "measure": "peripheral blood pressure", 
                "safety_issue": "No", 
                "time_frame": "4-8 weeks"
            }, 
            {
                "description": "After 2-week maintenance treatment when the RHR was \u226465 bpm or at 8-week final visit", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "4-8 weeks"
            }
        ], 
        "source": "Ruijin Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ruijin Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}